UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective

Clinical breast cancer, 2016-04, Vol.16 (2), p.73-81

2016

Volltextzugriff (PDF)

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Clinical cancer research, 2019-11, Vol.25 (21), p.6309-6319

2019

Volltextzugriff (PDF)

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-07, Vol.22 (13), p.3157-3163

2016

Volltextzugriff (PDF)

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Clinical cancer research, 2021-08, Vol.27 (16), p.4511-4520

2021

Volltextzugriff (PDF)

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Clinical cancer research, 2017-07, Vol.23 (14), p.3638-3648

2017

Volltextzugriff (PDF)

Evolution of Bevacizumab-Based Therapy in the Management of Breast Cancer

Clinical breast cancer, 2008-10, Vol.8 (5), p.402-410

2008

Volltextzugriff (PDF)

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

British journal of clinical pharmacology, 2020-09, Vol.86 (9), p.1836-1848

2020

Volltextzugriff (PDF)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

Breast cancer research and treatment, 2021-02, Vol.185 (3), p.759-771

2021

Volltextzugriff (PDF)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Clinical cancer research, 2022-08, Vol.28 (15), p.3214-3224

2022

Volltextzugriff (PDF)

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical cancer research, 2021-01, Vol.27 (2), p.447-459

2021

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Clinical cancer research, 2016-02, Vol.22 (4), p.827-836

2016

Volltextzugriff (PDF)

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

Cancer chemotherapy and pharmacology, 2022-01, Vol.89 (1), p.93-103

2022

Volltextzugriff (PDF)

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

JAMA oncology, 2021-02, Vol.7 (2), p.271

2021

Volltextzugriff (PDF)

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

Breast cancer research and treatment, 2020-10, Vol.183 (3), p.617-627

2020

Volltextzugriff (PDF)

Update on Precision Medicine in Breast Cancer

Cancer treatment and research, 2019, Vol.178, p.45-80

2019

Volltextzugriff (PDF)

Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer

Clinical breast cancer, 2012-02, Vol.12 (1), p.19-29

2012

Volltextzugriff (PDF)

Does race affect outcomes in triple negative breast cancer?

Breast cancer : basic and clinical research, 2010-05, Vol.4, p.23-33

2010

Volltextzugriff (PDF)

Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer

Radiology. Imaging cancer, 2023-03, Vol.5 (2), p.e220022-e220022

2023

Volltextzugriff (PDF)

Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT046-CT046

2016

Volltextzugriff (PDF)

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8063-8063

2015

Volltextzugriff (PDF)

Dantrolene sodium for the treatment of aldesleukin-induced rigors in a melanoma patient

The Annals of pharmacotherapy, 2012-05, Vol.46 (5), p.e11

2012

Volltextzugriff (PDF)

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3091-3091

2020

Volltextzugriff (PDF)

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER

Journal of cancer & allied specialties, 2016-05, Vol.2 (1)

2016

Volltextzugriff (PDF)

Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3073-3073

2021

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(79)
Buchkapitel
(1)

Sprache

Englisch
(80)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Oncology
(22)
Humans
(18)
Female
(14)
Middle Aged
(11)
Aged
(9)
Adult
(8)
Male
(8)
Aged, 80 And Over
(7)
Antineoplastic Agents - Therapeutic Use
(6)
Treatment Outcome
(6)
Breast Neoplasms - Drug Therapy
(5)
Neoplasms - Drug Therapy
(5)
Breast Cancer
(4)
Hematology, Oncology And Palliative Medicine
(4)
Patients
(4)
Antitumor Activity
(3)
Cancer
(3)
Cancer Research
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Evolution of Bevacizumab-Based Therapy in the Management of Breast Cancer

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

Update on Precision Medicine in Breast Cancer

Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer

Does race affect outcomes in triple negative breast cancer?

Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer

Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

Dantrolene sodium for the treatment of aldesleukin-induced rigors in a melanoma patient

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER

Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST)

Suchergebnisse filtern